Moderna, Bayer-backed startup Metagenomi files for US IPO
Metagenomi Technologies, a genetic medicines company backed by Bayer Healthcare and Moderna, filed for an initial public offering (IPO) in the United States on Friday (Jan 5).
The startup, launched in 2018 by UC Berkeley scientists, joins a slew of companies gearing up for a 2024 listing after a stock rally in recent months.
Growing expectations that the Federal Reserve could guide the economy to a soft landing is boosting confidence after a dismal spell late last year.
Earlier this week, KKR-backed BrightSpring Health Services also submitted paperwork for a Nasdaq listing
Metagenomi is developing therapies for genetic diseases. All of its revenue has been generated from three collaboration agreements, including one with Moderna, and not any product sales.
For the nine months ended Sep 30, 2023, its collaboration revenue surged nearly three-fold, to US$32.36 million.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Loss was US$48.96 million in the same period, compared to US$28.97 million a year earlier.
Metagenomi will aim to list on the Nasdaq under the symbol “MGX”. JPMorgan, Wells Fargo and Jefferies are among the underwriters for the IPO.
The filing comes a year after the Emeryville, California-based company raised US$275 million in a private funding round. REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Prudential shutters Hong Kong wealth unit Pulse
Singapore has to be realistic on global trends plaguing its stock market: DPM Wong
Google DeepMind unveils next generation of drug discovery AI model
AEM Holdings Q1 net profit tumbles 85% to S$2.4 million
World’s biggest tea buyer Lipton’s sale of last farms is a strategy shift
JPMorgan, Nomura limit Segantii exposure on Hong Kong case